FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach

The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.

...

Former IRS employee charged in $2.1 million Exxon Mobil tax credit theft attempt in Utah

1 week ago

Norway wealth fund to vote against Musk's $56 billion Tesla pay package

1 week ago

GameStop tumbles 40% as 'Roaring Kitty' trader says little new about retailer on livestream

1 week ago

Trump claims credit for Biden’s insulin price cap

1 week ago

DOJ settles CityMD Covid fraud allegations for $12 million

1 week ago